Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 300 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 12.4
- Book Value ₹
- Dividend Yield %
- ROCE 61.5 %
- ROE 59.0 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 63.1%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 87 | 131 | 132 | 203 | |
| 80 | 120 | 111 | 171 | |
| Operating Profit | 7 | 11 | 21 | 33 |
| OPM % | 8% | 8% | 16% | 16% |
| 0 | 0 | 1 | 2 | |
| Interest | 0 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 1 |
| Profit before tax | 7 | 11 | 20 | 33 |
| Tax % | 25% | 27% | 27% | 26% |
| 5 | 8 | 15 | 24 | |
| EPS in Rs | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 64% |
| TTM: | 67% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| Last Year: | 59% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 10 |
| Reserves | 5 | 13 | 28 | 44 |
| 6 | 11 | 13 | 17 | |
| 12 | 12 | 12 | 16 | |
| Total Liabilities | 25 | 37 | 54 | 86 |
| 1 | 6 | 5 | 9 | |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| 24 | 32 | 48 | 77 | |
| Total Assets | 25 | 37 | 54 | 86 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -6 | 0 | -0 | 4 | |
| -1 | -5 | -0 | -4 | |
| 7 | 5 | 0 | 3 | |
| Net Cash Flow | -0 | 0 | -0 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 80 | 62 | 87 | 82 |
| Inventory Days | 9 | 25 | 27 | 50 |
| Days Payable | 41 | 34 | 33 | 23 |
| Cash Conversion Cycle | 49 | 53 | 81 | 109 |
| Working Capital Days | 50 | 56 | 100 | 105 |
| ROCE % | 58% | 63% | 62% |
Documents
Annual reports
No data available.
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.